BioBrief

Friday, May 15: Enhertu’s Early Breast Cancer Expansion, Tecentriq’s MRD Approval, and Aardvark’s Clinical Hold

BioBrief’s Friday episode covers a regulatory-heavy day in biopharma, with two meaningful FDA oncology decisions landing against a weak biotech tape. In today’s BioBrief: * Enhertu — The FDA approved AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate in two early-stage HER2-positive breast cancer settings, including adjuvant use after residual invasive disease. * Tecentriq and Signatera — Roche’s Tecentriq was approved for ctDNA-positive muscle-invasive bladder cancer after cystectomy, alongside Natera’s Signatera CDx companion diagnostic. * Aardvark Therapeutics — The FDA placed ARD-101 under a full clinical hold after cardiac safety concerns, resetting the outlook for the company’s Prader-Willi syndrome program. * Market pulse — Biotech underperformed the broader market, with XBI down 3.08 percent and IBB down 2.63 percent versus a 1.2 percent decline in the S&P 500. * Catalyst watch — Next steps include Enhertu adoption in earlier breast cancer, real-world uptake of MRD-guided bladder cancer treatment, and Aardvark’s planned unblinding of available Phase 3 data. Today’s theme: strong FDA oncology decisions, weak biotech risk appetite, and a reminder that safety can quickly reshape a small-cap development story.

Week Ahead by BioBrief, Sunday, May 17: Ralinepag’s PAH Data, ASCO Abstracts, and Enhertu’s FDA Approvals

BioBrief’s special week-ahead edition previews the key biotech and biopharma events to watch for the week of May 18, with pulmonary data, oncology positioning, and FDA regulatory updates in focus. In today’s BioBrief: * United Therapeutics / ralinepag — Phase 3 ADVANCE OUTCOMES data in pulmonary arterial hypertension showed a 55 percent reduction in clinical worsening risk, setting up a planned NDA filing in the second half of 2026. * ASCO abstracts — Regular ASCO abstracts are scheduled for release on Thursday, May 21, creating an important oncology positioning event ahead of the full meeting. * Enhertu — Daiichi Sankyo and AstraZeneca enter the week with two new FDA approvals for Enhertu in HER2-positive early-stage breast cancer. * ATS respiratory watch — United Therapeutics’ Tyvaso data in idiopathic pulmonary fibrosis, Insmed’s ARIKAYCE data in MAC lung disease, and Savara’s molgramostim updates are also in focus. * Market pulse — Biotech enters the week under pressure, with XBI down about 3 percent last week and IBB down about 1.8 percent, while the S&P 500 was slightly positive. * Catalyst watch — The week’s core question is whether strong pulmonary data and ASCO setup can offset a risk-off small-cap biotech tape. This episode is designed for biotech investors, operators, founders, pharma BD teams, analysts, and scientifically literate listeners tracking clinical, regulatory, and market-moving events.

Thursday, May 14: Kyverna’s Autoimmune CAR-T Filing, BridgeBio’s Encaleret NDA, and Agios’ Mitapivat sNDA

BioBrief covers a selective biotech session driven by regulatory execution, rare-disease filings, and continued investor interest in differentiated clinical-stage stories. In today’s BioBrief: * Kyverna / miv-cel — Kyverna continued to rally after initiating a rolling BLA submission for miv-cel in stiff person syndrome, a potential milestone for autoimmune CAR-T therapy beyond oncology. * BridgeBio / encaleret — BridgeBio’s encaleret NDA in autosomal dominant hypocalcemia type 1 remained in focus after Phase 3 CALIBRATE data showed strong calcium-normalization results versus standard therapy. * Agios / mitapivat — Agios advanced mitapivat through an sNDA seeking accelerated approval in sickle cell disease, with FDA alignment on the confirmatory trial design. * Bristol Myers Squibb / Hengrui Pharma — Bristol Myers’ broad Hengrui collaboration continued to shape discussion around China-originated pipeline sourcing and large-pharma business development. * Market pulse — XBI rose about 0.9 percent while IBB gained about 0.3 percent, with investors rewarding clear regulatory and clinical catalysts rather than broad speculative risk. * Catalyst watch — Watch for Kyverna’s BLA completion and filing acceptance, BridgeBio’s NDA review designation, and upcoming Agios hematology data visibility. Today’s episode is about regulatory execution and modality validation driving biotech performance more than broad market risk appetite.

Wednesday, May 13: FDA Leadership Uncertainty, Bristol Myers’ Hengrui Deal, and Kyverna’s Autoimmune CAR-T Filing

BioBrief covers a selective biotech session shaped by regulatory uncertainty, large-pharma pipeline sourcing, and concrete FDA filing progress. In today’s BioBrief: * FDA leadership — Leadership uncertainty at the agency became a market catalyst, lifting some FDA-sensitive biotech names while keeping regulatory predictability in focus. * Bristol Myers Squibb / Hengrui Pharma — Bristol Myers announced a broad collaboration covering 13 programs across oncology, hematology, and immunology, with $600 million upfront and up to $15.2 billion in potential value. * Kyverna / miv-cel — Kyverna began a rolling BLA submission for miv-cel in stiff person syndrome, potentially moving autoimmune CAR-T therapy closer to formal FDA review. * Agios and BridgeBio — Agios submitted an sNDA for mitapivat in sickle cell disease, while BridgeBio filed an NDA for encaleret in autosomal dominant hypocalcemia type 1. * Market pulse — XBI rose about 0.7 percent and IBB gained about 0.2 percent, with investors rewarding regulatory clarity and specific catalysts more than broad small-cap risk. * Catalyst watch — Watch for FDA leadership updates, Kyverna filing acceptance, and future regulatory timelines for Agios and BridgeBio. Today’s episode is about regulatory uncertainty and strategic pipeline sourcing driving biotech sentiment more than broad risk appetite.

Tuesday, May 12: Bristol Myers’ Hengrui Deal, MoonLake’s Sonelokimab Path, and Agios / BridgeBio FDA Filings

BioBrief covers a selective biotech session where large-cap quality outperformed, pharma business development stayed active, and regulatory-path clarity drove several company-specific stories. In today’s BioBrief: * Bristol Myers Squibb / Hengrui Pharma — BMS announced a broad collaboration covering 13 oncology, hematology, and immunology programs, with $600 million upfront and up to about $15.2 billion in potential total value. * MoonLake / sonelokimab — FDA feedback suggests MoonLake may be able to support a future BLA in hidradenitis suppurativa using existing VELA-1, VELA-2, and MIRA data, reducing the perceived need for another HS trial. * Agios / mitapivat — Agios submitted an sNDA seeking accelerated approval in sickle cell disease, with FDA alignment on the confirmatory trial design. * BridgeBio / encaleret — BridgeBio submitted an NDA for encaleret in autosomal dominant hypocalcemia type 1, extending its rare-disease regulatory pipeline. * Market pulse — XBI finished roughly flat, while IBB gained about 1.3 percent, pointing to a selective biotech tape favoring larger-cap and catalyst-backed names. * Regulatory watch — Reports of FDA leadership transition added a broader note of uncertainty around regulatory predictability, though no product-specific review changes were identified. Today’s episode is about selective biotech confidence: pharma is still paying for external innovation, and FDA-path clarity remains a key driver for late-stage biotech stories.